Mind Medicine (MindMed) I... (MNMD)
6.07
-0.65 (-9.67%)
At close: Mar 03, 2025, 3:59 PM
6.08
0.23%
After-hours: Mar 03, 2025, 07:56 PM EST
No 1D chart data available
| Bid | 6.08 |
| Market Cap | 445.12M |
| Revenue (ttm) | 4.55M |
| Net Income (ttm) | -92.06M |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -3.55 |
| Forward PE | -4.85 |
| Analyst | Buy |
| Ask | 6.24 |
| Volume | 1,590,192 |
| Avg. Volume (20D) | 1,958,243 |
| Open | 6.79 |
| Previous Close | 6.72 |
| Day's Range | 6.04 - 6.88 |
| 52-Week Range | 5.03 - 12.22 |
| Beta | 2.40 |
About MNMD
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has com...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 15, 2016
Employees 57
Stock Exchange NASDAQ
Ticker Symbol MNMD
Website https://www.mindmed.co
Analyst Forecast
According to 10 analyst ratings, the average rating for MNMD stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 245.96% from the latest price.
Buy 90.00%
Hold 0.00%
Sell 0.00%
1 month ago
+7.68%
Mind Medicine shares are trading higher after Ever...
Unlock content with
Pro Subscription
3 months ago
+5.65%
Mind Medicine shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.
